Apolipoprotein C2 (Apo CII) Antibody
1690€ (1 mg)
Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.
935106861
info@markelab.com
name
Apolipoprotein C2 (Apo CII) Antibody
category
Primary Antibodies
provider
Abbexa
reference
abx023243
tested applications
ELISA, WB
Description
Apo CII Antibody is a Rabbit polyclonal antibody for lipoproteins against Apo CII.
Documents del producto
Instrucciones
Data sheet
Product specifications
| Category | Primary Antibodies |
| Immunogen Target | Apolipoprotein C2 (Apo CII) |
| Host | Rabbit |
| Reactivity | Human |
| Recommended Dilution | Optimal dilutions/concentrations should be determined by the end user. |
| Clonality | Polyclonal |
| Conjugation | Unconjugated |
| Purification | Purified by affinity chromatography. |
| Size 1 | 1 mg |
| Form | Liquid |
| Tested Applications | ELISA, WB |
| Buffer | Buffer contains NaN3 as a preservative. |
| Availability | Shipped within 10-20 working days. |
| Storage | Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles. |
| Dry Ice | No |
| Alias | APOC2, APO-CII, APOC-II, apolipoprotein C2,Apolipoprotein C-II |
| Background | Antibody anti-APOC2 |
| Status | RUO |
Descripción
APOC2 is a key component of VLDL and chylomicrons, playing an essential role in triglyceride metabolism as an activator of lipoprotein lipase (LPL). APOC2 is primarily synthesized in the liver and secreted into the plasma, where it facilitates the hydrolysis of triglycerides in chylomicrons and VLDL into free fatty acids and glycerol for energy production or storage. A deficiency or mutation in the APOC2 gene leads to familial chylomicronemia syndrome (FCS), a rare genetic disorder characterized by elevated triglyceride levels, severe hyperlipidemia, and recurrent pancreatitis. APOC2 levels are tightly regulated to maintain lipid balance, as excess or reduced APOC2 activity can disrupt triglyceride clearance and promote atherosclerosis. APOC2 functions cooperatively with other apolipoproteins, such as APOA5 and APOE, to regulate lipid metabolism. Therapeutic strategies targeting APOC2 pathways are being explored to improve triglyceride clearance and reduce cardiovascular risk in individuals with dyslipidemia.
Related Products
Human APOC2 (Apolipoprotein C-II) ELISA Kit
Ver Producto
Monkey APOC2 (Apolipoprotein C-II) ELISA Kit
Ver Producto